key articles
Comparative evaluation of the safety and efficacy of long-term use of anticholinergics in OAB patients
Tuesday, 1 November 2011- Overactive bladder (OAB) is a chronic disease, but comparative trials of anticholinergics, which are commonly used for treatment of OAB, have generally been performed for up to 12 weeks only. There is no...
Edited by: JV
Perception of bladder fullness and bladder volume in OAB patients
Friday, 23 September 2011- R. Heeringa and colleagues evaluated the reliability of the degree of urge and perception of bladder fullness scales, the relationship between the scales and bladder volume, and possible differences...
Edited by: JV
Videourodynamic changes of BoNT-A in patients with neurogenic bladder dysfunction
Monday, 5 September 2011- S. H. Alloussi and colleagues conducted a study to document the videourodynamic changes and the efficacy and safety profile of botulinum toxin A (BoNT-A, Dysport®) in neurogenic bladder dysfunction (NBD)...
Edited by: JV
Urinary incontinence in men after one-to-one pelvic-floor muscle training following RP
Monday, 1 August 2011- Urinary incontinence is common immediately after prostate surgery. Men are often advised to do pelvic-floor exercises, but evidence to support this is inconclusive.
C. Glazener and colleagues conducted a...
Edited by: JV
Role of Botox-A in refractory idiopathic OAB patients without detrusor overactivity
Monday, 20 June 2011- P. Kanagarajah and colleagues conducted a study to evaluate the efficacy of intradetrusor botulinum toxin-A (BTX-A) in idiopathic overactive bladder patients (OAB) refractory to anti-muscarinic therapy,...
Edited by: JV
Mixed results for new OAB drugs
Monday, 30 May 2011- Overactive bladder (OAB) symptoms declined significantly within four weeks after the start of treatment with the investigational beta-3 agonist mirabegron, data from a randomised, placebo-controlled trial...
Edited by: JV
Immediate effect on OAB symptoms following use of imidafenacin
Monday, 2 May 2011- One of the factors influencing the treatment compliance of patients with overactive bladder (OAB) symptoms is thought to be the time to reach clinical effectiveness after administering drugs.
Y. Kitagawa and...
Edited by: JV
Caffeine intake, and the risk of stress, urgency and urinary incontinence
Friday, 22 April 2011- Although caffeine consumption is common and generally believed to affect bladder function, little is known about caffeine intake and incident urinary incontinence. Y. Jura and colleagues conducted a study...
Edited by: JV
Assessing the efficacy and tolerability of trospium XR in OAB
Wednesday, 13 April 2011- Once-daily extended-release (XR) trospium chloride has been evaluated for the treatment of overactive bladder syndrome (OAB) in two 12-week randomised, double-blind, placebo-controlled studies. This...
Edited by: JV
26th Annual EAU Congress: efficacy and safety of mirabegron in OAB
Monday, 28 March 2011- At the 26th Annual EAU Congress in Vienna, selected abstracts were highlighted for presenting some remarkable findings. Below is an extract of Abstract 885 by V. Nitti and colleagues on improvement of OAB...
Edited by: JV
